跳至主要内容
临床试验/NCT06620913
NCT06620913进行中(未招募)不适用

Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity

Hospices Civils de Lyon1 个研究点 分布在 1 个国家目标入组 232 人开始时间: 2024年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
232
试验地点
1
主要终点
Modified Rankin Scale (mRs)

研究概览

简要总结

Paraneoplastic neurological syndromes are rare syndromes caused by the remote effects of cancer. They have an immune-mediated pathogenesis, yet the underlying mechanisms are not fully elucidated. CV2/Collapsin response-mediator protein 5 (CRMP5)-IgG paraneoplastic neurological syndrome is characterized by heterogeneous clinical presentations, affecting both central and peripheral nervous system, and the most frequently associate tumor is small cell lung carcinoma. Central nervous system involvement along with CSF and neuroimaging findings have not been fully described in the literature in CV2/CRMP5 patients. Unraveling the complexities of CV2/CRMP5 paraneoplastic neurological syndrome is critical to improve diagnosis, treatment, and patients' care. Our intention is to perform a comprehensive analysis of the clinical characteristics and instrumental investigations of a large cohort of CV2/CRMP5 patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient with paraneoplastic neurological syndromes
  • Patient with CV2 antibody in sera and/or CSF

排除标准

  • Patient with no data
  • Patient without neurological disorder
  • Patient without CV2 antibody in sera/CSF

结局指标

主要结局

Modified Rankin Scale (mRs)

时间窗: At baseline, 3, 6, 12, 18 month

Application of modified rankin scale

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验